Neuracle's NEO brain implant wins China approval before Neuralink
The Shanghai startup's device is cleared only for a narrow group of spinal cord injury patients, but it moves invasive BCIs past trials.
By Ryan Merket · Published
Primary source: MIT Technology Review
Why it matters
Neuracle's approval turns invasive BCIs from a lab and trial story into a regulated medical product story, while giving China an early lead in a field long defined by U.S. attention around Neuralink.
Neuracle Technology's NEO brain-computer interface became the first invasive BCI product approved for use beyond clinical trials, MIT Technology Review reported, giving the Shanghai startup a regulatory milestone ahead of better-known rivals including Neuralink.…